Bernie Sanders im­plores No­vo to cut list prices of Ozem­pic, We­govy

Sen­ate HELP Com­mit­tee Chair Bernie Sanders (I-VT) is call­ing on No­vo Nordisk to dra­mat­i­cal­ly low­er the list prices of Ozem­pic and We­govy. It’s the lat­est move in the sen­a­tor’s en­deav­or to low­er the cost of pre­scrip­tion med­i­cines.

In a press re­lease Wednes­day, Sanders un­der­scored that Ozem­pic and We­govy cost hun­dreds of dol­lars less in oth­er coun­tries and urged No­vo to low­er its US price to no more than what it charges in Cana­da, where the list price is $155. No­vo cur­rent­ly charges a list price of about $936 for a month­ly sup­ply of the di­a­betes drug Ozem­pic, and $1,350 for a month­ly sup­ply of the obe­si­ty ver­sion mar­ket­ed as We­govy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER